- Chase Kasper, MBA, RTTP, Senior Deputy Director and UIDP Primary Representative for Clemson University
- Uma Kaundinya, Officer at Stanford Angels & Entrepreneurs; Strategic Advisor at Prime Row Ventures
- The University of Nevada, Las Vegas
- The University of Wyoming
- Vanderbilt Center for Technology Transfer and Commercialization
- On Monday, June 16, to Thursday, June 19,the Biotechnology Innovation Organization (BIO) will host BIO 2025. Held in Boston, MA, the industry’s premier event will feature industry speakers, educational programs, networking opportunities, and thousands of attendees from over 70 countries across the global biotech ecosystem.
Does your organization have an upcoming event? We’d love to feature it in our newsletter and events calendar! Submit the information here.

This month’s member spotlight is Dr. Carol Mimura, Assistant Vice Chancellor, Intellectual Property & Industry Research Alliances (IPIRA) at the University of California, Berkeley! Dr. Mimura came to UC Berkeley as a postdoctoral fellow in biochemistry, where she performed research and was exposed to the business side of science. After gaining experience in the private sector, she later joined UC Berkeley’s Office of Technology Licensing and, in 2004, established IPIRA. She credits her talented staff with spinning out more than 300 startups based on Berkeley IP rights and increasing the number of industrial sponsors of research from 100 to more than 1,400 companies, advancing innovations in fields including medicine, cleantech, robotics, and new materials. In 2023, Dr. Mimura received the Bayh-Dole Coalition’s inaugural American Innovator Award for commercializing Nobel Prize-winning research that led to the revolutionary cancer immunotherapy Yervoy™. The Coalition is grateful to have Dr. Mimura as a member and a passionate advocate for the virtuous cycle of innovation fostered by the Bayh-Dole Act.
“Since 1993, I have had the privilege of witnessing the impact of the Bayh-Dole Act firsthand. Take James P. Allison’s groundbreaking immunotherapy, Yervoy™, for example. Had UC Berkeley not been allowed to patent and license his work, thanks to the Bayh-Dole Act, that discovery might never have progressed beyond experiments in mice to reach human clinical trials, and ultimately, the market, offering a life-saving treatment to millions of cancer patients. The FDA’s approval of Yervoy™ in 2011 also jump-started worldwide investment in the immunotherapy field.* UC Berkeley used a portion of the profits from licensing its patent to finance a new research building where broad applications of its next Nobel-prize-winning research, CRISPR, led by Jennifer Doudna, were being developed. Bayh-Dole enables the translation of high-risk research into real-world solutions and fuels a continuous cycle of discovery, translation, and reinvestment into the research enterprise. The Bayh-Dole Act bolsters scientific progress, economic prosperity, and national security by supporting research and education that fosters innovation and trains future scientists.” — Dr. Carol Mimura, Assistant Vice Chancellor, Intellectual Property & Industry Research Alliances (IPIRA), at the University of California, Berkeley
*President Jimmy Carter, who signed the Bayh-Dole Act, himself benefited from immunotherapy. I wonder if he felt a sense of awe and validation that a law that he signed into existence prolonged his life and the lives of many others around the world.